Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class ASSE: 688505

Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of FZ-P001 Sodium for Injection for Visualization of Malignant Lesions during Ovarian Cancer Surgery

· Issued by Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange

On 6ix: 6ix.com/news/announcement-on-voluntary-disclosure-of-completion-of-inclusion-of-the-first-subject-in-phase-1-clinical-trial-of-fz-p001-sodium-for-injection-for-visualization-of-malignant-lesions-during-ovarian-cancer-surgery

Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of FZ-P001 Sodium for Injection for Visualization of Malignant Lesions during Ovarian Cancer Surgery

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis

Earlier from Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A

All Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A news releases